Health Journal Online

Tag: Single

  • How a Single Meal Can Cripple Your Arteries and Lungs

    How a Single Meal Can Cripple Your Arteries and Lungs

    What happens within hours of eating a high-fat meal?

    We are only as old as our arteries. What can we do to preserve arterial function as we age? A poor diet and sedentary behavior can lead to adverse aging processes, like impairment of the little power plants in our cells, which can result in free radical formation, oxidative stress, and inflammation, which lead to the artery dysfunction that can end in cardiovascular disease that ends us.

    In a series of videos I did about a decade ago, I discussed landmark research showing that a single high-fat meal could cripple artery function within hours of consumption, compared to no change with a low-fat meal, as you can see below and at 1:04 in my video Saturated Fat Causes Artery and Lung Inflammation.

    In the study, the high-fat meal that so crippled artery function included Sausage and Egg McMuffins from McDonald’s. How do we know the sausage, egg, or cheese was to blame? What about the crappy carbohydrates in the biscuits or something else? Because the low-fat meal that didn’t impair artery function was a sugary mess of carby Frosted Flakes.

    Just when your artery function finally starts to recover, five or six hours later—it’s lunchtime! Then, your arteries may get whacked with another load of meat, eggs, dairy, or oil. Why does it matter so much what happens after a meal within your body? Because most of us spend about 16 hours a day in that after-a-meal state, constantly hammering our arteries. No wonder cardiovascular disease is our number one killer.

    And it doesn’t just inflame the arteries in our heart but our lungs as well. “A high-fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma.” When people with asthma coughed up sputum from their lungs four hours after the same kind of high-fat meal, inflammatory cells shot up in the high-fat meal group, as you can see below and at 2:12 in my video.

    In terms of lung function, when given two hits of their inhalers (containing a drug called albuterol or Ventolin), their airways open up as they should after a low-fat meal. But after the high-fat meal, the same inhaler doses don’t work as well, crapping out after a few hours because of all the extra inflammation in their lungs, as you can see below and at 2:29 in my video.

    What you eat can determine how well you breathe.

    But those study participants were people with asthma. Well, researchers found that even people without asthma have that same spike in inflammatory cells in sputum coughed out of their lungs four hours after eating what was, in this case, “a Jimmy Dean’s Meat Lover’s breakfast bowl.”

    And there aren’t only more inflammatory cells; there is a doubling of the amount of pro-inflammatory oxidized LDL cholesterol sucked up by the type of white blood cells that go on to form foam cells. Those are the cells that build up the inflamed pus in your artery wall that leads to heart attacks. All this happens within just hours of eating pizza, in this case. The fat in your blood goes up, and so do your endotoxin levels, as you can see below and at 3:16 in my video.

    Endotoxins are the components of bacterial cell walls, and foods like meat can be so contaminated with bacteria—alive and dead—that they accumulate endotoxins. We’re talking about both red meat and white meat, as you can see below and at 3:28 in my video.

    But recent research (published in 2020) suggests the main culprit may not be endotoxins after all, but the fat itself. The saturated fat floating in your blood after an unhealthy meal may be inducing the inflammation more directly. Either way, we are responsible for what we eat, meal by meal, in shaping the risk factors for chronic metabolic disease.

    Doctor’s Note

    This topic is the first in a three-part series on saturated fat and fast food. The next two are Exercising to Protect Your Arteries from Fast Food and Foods to Help Protect Your Arteries from Saturated Fat.

    What about the “butter is back” studies? See the related posts below.



    Source link

  • Inside Life Medical’s Growth from a Single Service into a Broader Medical Ecosystem

    Inside Life Medical’s Growth from a Single Service into a Broader Medical Ecosystem

    Life Medical‘s growth story is rooted in a simple question that continues to guide its direction: how can care be delivered in a way that better reflects how patients actually live? According to CEO Dov Brafman, the company did not begin with an ambition to build a multi-specialty organization. Instead, it emerged through a series of practical decisions shaped by firsthand exposure to gaps in care delivery.

    Approximately eight years ago, Life Medical officially launched as a medical transportation service. Brafman explains that the original focus was straightforward, helping patients travel safely between medical appointments and their homes. “Transportation was a very tangible entry point,” he notes. “It allowed us to support people in a way that was immediately useful, while also giving us visibility into how fragmented care can feel from a patient’s perspective.”

    Through those early interactions, Brafman began communicating with providers, facilities, and caregivers across different parts of the healthcare landscape. Those conversations, he says, highlighted recurring challenges around continuity and access once patients returned home. It was during this period that he met Michelle Werner, VP at Life Medical, whose background was rooted in in-home support services. Their discussions prompted a broader consideration of how Life Medical might expand beyond logistics alone.

    “The question became, why stop at transportation?” Brafman explains. “If we were already serving people at critical transition points, it made sense to think about what additional support could look like.” That curiosity led to Life Medical’s first expansion into in-home assistance, marking the beginning of a multi-service approach that would later define the organization.

    From there, growth unfolded fast but, more importantly, thoughtfully. “Every service we have added has gone through the same set of questions,” Brafman explains. “Does it make operational sense, does it genuinely add value for patients, and do we have the right leadership in place to execute it well? Over time, that approach is what led us to build a broader ecosystem that includes urgent clinical care, ongoing medical support, rehabilitation, palliative care, mobile imaging, private homecare, and hospice.”

    A defining characteristic of Life Medical’s expansion has been its emphasis on leadership readiness. While clinical hiring follows established standards and credentialing processes, Brafman says leadership roles receive exceptional scrutiny. “If we are entering a new area of care, the person leading that service is critical,” he explains. “That’s where I’ll take my time. I’m comfortable waiting as long as it takes to find the right individual.”

    This deliberate approach reflects a belief that execution depends less on speed and more on alignment. From Brafman’s perspective, innovation is not just about introducing new services, but about ensuring those services integrate seamlessly into the broader system. “We look at whether something fits within the ecosystem we are building,” he says. “If it doesn’t connect meaningfully, it’s probably not something we pursue.”

    Life Medical

    Life Medical’s service offerings have expanded alongside this philosophy. Rather than positioning services as standalone units, the organization emphasizes coordination across care stages. According to Brafman, this structure helps reduce gaps that can emerge when patients move between different forms of support. “It allows clinicians and care teams to stay connected with patients in a more continuous way,” Brafman says. “That engagement might begin in an urgent care setting, transition into support in the home, and, when appropriate, extend into longer-term clinical oversight.”

    Brafman also points to the importance of adaptability. “Healthcare needs are not static,” he explains. “They change based on circumstance, environment, and timing. Our goal has been to build a system that can respond to those changes without adding unnecessary complexity for patients.”

    Today, Life Medical operates as a multi-specialty medical organization shaped by years of iteration rather than a single expansion moment. Its growth reflects an ongoing effort to align operational decisions with real-world patient experiences, guided by a leadership philosophy that prioritizes thoughtful execution over rapid scale. “The business has evolved by staying focused on the people we serve,” Brafman says. “Every step forward has been about asking what would make care feel more connected, more accessible, and more coherent for those relying on it.”

    Source link

  • Single Dose Of Existing Antibody Injection May Cut Hospitalizations

    Single Dose Of Existing Antibody Injection May Cut Hospitalizations

    For millions of people struggling with asthma or COPD, a higher dose of an existing antibody injection could be a total game changer, a recent trial results reveal.

    According to the study conducted by a research team from the University of Oxford and Kings College London, a single injection of a monoclonal antibody, benralizumab, could be more effective than standard steroid tablets during asthma or COPD flare-ups.

    Flare-ups, or attacks, occur when asthma symptoms suddenly worsen, causing shortness of breath, chest tightness or pain, coughing, and wheezing. Several factors such as respiratory infections, smoke, hot and humid air, or pollen can trigger flare-ups.

    Benralizumab is currently used to reduce inflammation in severe asthma by targeting specific white blood cells called eosinophils. Researchers have now found that repurposing the same drug at a higher dosage to manage “eosinophilic exacerbations” could reduce the need for further treatments by 30%.

    Eosinophilic exacerbations are a particular type of flare-up caused by elevated eosinophil levels. They constitute 30% of COPD flare-ups and almost 50% of asthma attacks.

    “This could be a game-changer for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in 50 years, despite causing 3.8 million deaths worldwide a year combined. Benralizumab is a safe and effective drug already used to manage severe asthma. We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets which is the only treatment currently available,” said lead investigator of the trial Professor Mona Bafadhel in a news release.

    During the trial, researchers evaluated 158 patients for asthma or COPD symptoms by assessing the severity of their cough, wheezing, breathlessness, and sputum. Participants were divided into three treatment groups: one received a benralizumab injection and dummy tablets, another received the standard of care (30 mg of prednisolone daily for five days) and a dummy injection, and the third group received both a benralizumab injection and the standard of care.

    Participants treated with benralizumab showed improved respiratory symptoms, including reduced cough, wheezing, breathlessness, and sputum, after 28 days. Additionally, the benralizumab group had four times fewer people that failed treatment compared to the standard of care with prednisolone.

    “Treatment with the benralizumab injection took longer to fail, meaning fewer episodes to see a doctor or go to hospital. There was also an improvement in the quality of life for people with asthma and COPD,” the news release stated.

    “Our study shows massive promise for asthma and COPD treatment. COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. We need to provide these patients with life-saving options before their time runs out,” Dr Sanjay Ramakrishnan, the first author of the trial said.

    Source link